Duchenne muscular dystrophy is a rare, progressive genetic disorder caused by mutations in the DMD gene, which encodes the protein dystrophin. Without functional dystrophin, muscle fibers weaken and degenerate over time, leading to severe mobility impairments, respiratory complications, and premature death, typically in the third or fourth decade of life. Current standard treatments, including corticosteroids and exon skipping therapies, slow disease progression but do not address the underlying genetic defect. Gene therapy represents a potential paradigm shift by delivering a functional copy of the DMD gene directly to muscle cells, offering the possibility of long term stabilization or even improvement in muscle function.
Regenxbio’s RGX 202 employs an adeno associated viral vector to deliver a micro dystrophin transgene to muscle tissue. In early stage clinical trials, the therapy demonstrated promising safety and efficacy signals, including increased micro dystrophin expression and stabilization of motor function in treated patients. However, the FDA’s request for an additional trial in March 2024 raised concerns about the robustness of the existing data package, particularly regarding long term durability and potential immune responses to the viral vector.
The company’s decision to proceed with submission despite this request suggests confidence in its existing dataset, which includes data from the ongoing Phase 1/2 AFFINITY DUCHENNE trial. Regenxbio executives have indicated that they believe the totality of the evidence, including preclinical and clinical data, supports the therapy’s potential benefit risk profile. The FDA’s response to the submission will be closely watched as a bellwether for how the agency evaluates gene therapies moving forward, particularly those targeting rare, life threatening diseases with limited treatment options.
DISCUSSION (0)